DCGI approves Phase 2, 3 clinical trials of COVAXIN on children aged 2 to 18 years
DCGI approves Phase 2, 3 clinical trials of COVAXIN on children aged 2 to 18 years
newKerala.com
0 shares
1 views
You might like
Related news coverage
NA Proactive news snapshot: TechX Technologies, Binovi Technologies, Versus Systems, Organic Garage, NEXE Innovations UPDATE …
Proactive Investors
TechX Technologies Inc (CSE:TECX) has entered into a debt settlement agreement pursuant to which the company has agreed to issue..
-
NA Proactive news snapshot: Star Royalties, Tocvan Ventures, CytoDyn, First Cobalt …
Proactive Investors
-
Covaxin trials for 2-18 age group to begin in 10-12 days: Niti Aayog’s Dr VK Paul
Zee News
-
COVID-19: Covaxin gets approval for phase 2-3 clinical trials for 2-18 age group, to begin in next 10-12 days
DNA
-
DCGI allows Phase II-III clinical trial of Covaxin on 2 to 18-years-old
newKerala.com
Advertisement
More coverage
DGCI gives nod for Covaxin Phase II/III trials on 2-18 year olds
IndiaTimes
The Indian drugs regulator, the Drugs Controller General of India (DCGI) has granted its approval to indigenously developed..
-
Covid-19: DCGI approves phase 2, 3 clinical trials of Covaxin on children aged 2 to 18 years
IndiaTimes
-
Bharat Biotech`s Covaxin gets DGCI nod to conduct clinical trials on children above 2 years
Zee News
-
DCGI approves Covaxin clinical trials for children aged 2-18 years
DNA
-
Covaxin gets nod for phase II/III trials on 2 to 18-year-olds
IndiaTimes